Spyre Therapeutics
SYRE
23 hedge funds and large institutions have $26.6M invested in Spyre Therapeutics in 2016 Q2 according to their latest regulatory filings, with 23 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$10.6M |
| 2 |
O
OrbiMed
New York
|
+$10.4M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$4.02M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$4M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$3.1M |
Top Sellers
SYRE Hedge Fund Activity: Q2 2016 in Review
23 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2016, worth a combined $26.6M.
Buyers outnumbered sellers: 23 funds opened new SYRE positions and 0 closed out — a net gain of 23 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $10.6M.
- 23 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $26.6M of Spyre Therapeutics stock for Q2 2016.
- 23 funds opened new Spyre Therapeutics positions in Q2 2016 and 0 closed out, a net change of +23 holders.
- The largest Spyre Therapeutics buyer in Q2 2016 was Jennison Associates, an estimated $10.6M added.
Based on aggregated 13F filings for Q2 2016.